Difference between revisions of "Team:SDU-Denmark/Tour72"
| Line 3: | Line 3: | ||
<h1> Medical aspects </h1> | <h1> Medical aspects </h1> | ||
| − | <p> Even though there is no doubt that peptide aptamers are potential rivals of traditional antibodies in medicine and therapy, some | + | <p> Even though there is no doubt that peptide aptamers are potential rivals of traditional antibodies in medicine and therapy, some hurtles have to be defeated before clinical implementation will be possible. </p> |
| − | < | + | <ul> |
| − | < | + | <li>Effector mechanism: Traditional antibodies have a Fab region, that bind to microbes of which they have specificity. Activation of the immune respons is conducted through their Fc region that interacts with Fc receptors on cell surfaces of lymphocytes and/or other effector cells of the immune system. Such a effector mechanism or something like it have to be attached to the peptide aptamer. |
| + | </li> | ||
| − | < | + | <li> The size of the peptide: The bigger molecule the larger risk of immunogenicity. To avoid an respons from the human immune system it is important that the peptide is as small as possible. If the immune system develops immunization against the peptide aptamer it will not have any function at all. </li> |
| − | + | ||
| + | <li> Half-life: Peptide aptamers targeted at chronic diseases have to have a very long degradation time. </li> | ||
| − | <h2> | + | |
| − | < | + | <h2>How can peptide aptamers treat disease?</h2> |
| + | <ul> | ||
| + | <li> By attaching small gold nanoparticles (sAuNPs) to the peptide aptamer it would be possible to detect the aptamer inside the body and target fx radiotherapi: | ||
| + | Recent studies have proved small gold nanoparticles (sAuNPs) as excellent vehicles for drug delivery and cancer therapy. sAuNPs are proven as excellent vehicles especially because of their high biocompatibily, large surface-to-volume ratio and strong diffusivit<span class="sourceReference">y</span>. | ||
| + | <span class="tooltip"> | ||
| + | <span class="tooltipHeader">Reference:</span> | ||
| + | Kim CS, et al. Cellular imaging of endosome entrapped small gold nanoparticles, 2015 Jun 10;2:306-15. doi: 10.1016/j.mex.2015.06.001. <a target="blank_" href="http://www.ncbi.nlm.nih.gov/pubmed/26151001de">(Link)</a> | ||
| + | </span> | ||
| + | </li> | ||
</html> | </html> | ||
{{:Team:SDU-Denmark/core/footer}} | {{:Team:SDU-Denmark/core/footer}} | ||
Revision as of 20:08, 9 September 2015
Medical aspects
Even though there is no doubt that peptide aptamers are potential rivals of traditional antibodies in medicine and therapy, some hurtles have to be defeated before clinical implementation will be possible.
- Effector mechanism: Traditional antibodies have a Fab region, that bind to microbes of which they have specificity. Activation of the immune respons is conducted through their Fc region that interacts with Fc receptors on cell surfaces of lymphocytes and/or other effector cells of the immune system. Such a effector mechanism or something like it have to be attached to the peptide aptamer.
- The size of the peptide: The bigger molecule the larger risk of immunogenicity. To avoid an respons from the human immune system it is important that the peptide is as small as possible. If the immune system develops immunization against the peptide aptamer it will not have any function at all.
- Half-life: Peptide aptamers targeted at chronic diseases have to have a very long degradation time.
- By attaching small gold nanoparticles (sAuNPs) to the peptide aptamer it would be possible to detect the aptamer inside the body and target fx radiotherapi: Recent studies have proved small gold nanoparticles (sAuNPs) as excellent vehicles for drug delivery and cancer therapy. sAuNPs are proven as excellent vehicles especially because of their high biocompatibily, large surface-to-volume ratio and strong diffusivity. Reference: Kim CS, et al. Cellular imaging of endosome entrapped small gold nanoparticles, 2015 Jun 10;2:306-15. doi: 10.1016/j.mex.2015.06.001. (Link)
How can peptide aptamers treat disease?